## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Ш

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Estimated average burden hours per response: 0.5

	conditions of Rule			
1. Name and Address OrbiMed Israe			2. Issuer Name and Ticker or Trading Symbol BiomX Inc. [ PHGE ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
Partnership			3. Date of Earliest Transaction (Month/Day/Year) 05/15/2024	Director X 10% Owner Officer (give title Other (specify below) below)
(Last) (First) (Middle) 5 HAHOSHLIM STREET, BUILDING B, 1ST FL.			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person
(Street) HERZLIYA				
PITUACH	L3	46686		
(City)	(State)	(Zip)		

## Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3) 2. Transa Date (Month/D)		2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock	05/15/2024		x		9,280,408	Α	\$0.244	13,797,997	Ι	See footnotes <sup>(2)(3)</sup>
Common Stock	05/15/2024		<b>S</b> <sup>(1)</sup>		24,344	D	\$0.3812	13,773,653	Ι	See footnotes <sup>(2)(3)</sup>

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (In 8)		Deriva Secur Acqui Dispo			d 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Warrants (Right to Buy)	\$0.244	05/15/2024		x			9,280,408	05/04/2023	05/04/2033	Common Stock	9,280,408	\$0	0	I	See footnotes <sup>(2)(3)</sup>

1. Name and Address of Reporting Person\*

OrbiMed Israel BioFund GP Limited Partnership

(Last)	(First)	(Middle)	
5 HAHOSHLIM	STREET, BUILDI	NG B, 1ST FL.	
(Street) HERZLIYA PITUACH	L3	46686	
(City)	(State)	(Zip)	

1. Name and Address OrbiMed Israe		on •						
(Last) 5 HAHOSHLIM S	(First) STREET, BUIL	(Middle) DING B, 1ST FL.						
(Street) HERZLIYA PITUACH	L3	46686						
(City)	(State)	(Zip)						
1. Name and Address GORDON CA		on •						
(Last) (First) (Middle) C/O ORBIMED ISRAEL GP LTD. 5 HAHOSHLIM STREET, BUILDING B, 1ST FL.								
(Street) HERZLIYA PITUACH	L3	46686						
(City)	(State)	(Zip)						
1. Name and Address <u>Chimovits Erec</u>		on*						
(Last) (First) (Middle) C/O ORBIMED ISRAEL GP LTD. 5 HAHOSHLIM STREET, BUILDING B, 1ST FL.								
(Street) HERZLIYA PITUACH	L3	46686						
(City)	(State)	(Zip)						

## Explanation of Responses:

1. On May 15, 2024, OrbiMed Israel Partners Limited Partnership ("OIP") exercised pre-funded warrants ("Warrants") to purchase 9,280,408 shares of the Issuer's common stock for \$0.244 per share. OIP paid the exercise price on a cashless basis, resulting in the Issuer withholding 24,344 of the Warrant shares to pay the exercise price and issuing to OIP the remaining 9,256,064 shares. The shares of the Issuer's common stock withheld to pay the exercise price of the Warrants are matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), with a portion of OIP's purchase of certain derivative securities on March 15, 2024. OIP will disgorge to the Issuer the statutory "profits" pursuant to Section 16(b) of the Exchange Act of 1934, as amended from such transactions.

2. These securities are held of record by OIP. OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund") is the general partner of OIP and OrbiMed Israel GP Ltd. ("OrbiMed Israel") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Israel exercises investment and voting power through an investment committee comprised of Carl L. Gordon and Erez Chimovits.

3. Each of OrbiMed Israel, OrbiMed BioFund, Carl L. Gordon, and Erez Chimovits disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

/s/ Carl L. Gordon	05/20/2024
/s/ Erez Chimovits	05/20/2024
<u>/s/ Carl L. Gordon, Director,</u> OrbiMed Israel GP Ltd.	05/20/2024
<u>/s/ Carl L. Gordon, Director,</u> OrbiMed Israel BioFund GP Limited Partnership	<u>05/20/2024</u>
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.